Close Menu

NEW YORK (GenomeWeb) – QED Therapeutics said today that it has partnered with Foundation Medicine to develop a companion diagnostic for its drug candidate infigratinib in patients with cholangiocarcinoma (bile duct cancer).

Infigratinib is an FGFR1-3-selective tyrosine kinase inhibitor, and the CDx will include the detection of activating FGFR2 fusions. It is expected to be incorporated into FoundationOne CDx, Foundation Medicine's FDA-approved comprehensive genomic profiling assay for all solid tumors, which includes several companion diagnostics.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to NPR, an antibody-based test could identify people who were exposed to SARS-CoV-2 and either didn't develop symptoms or were misdiagnosed.

A sequencing analysis of New York City rats indicates they have adapted to the urban environment there, according to a recent preprint.

Ars Technica reports that a multicellular eukaryotic parasite has lost its mitochondria.

In Science this week: perspective piece says AI can accelerate drug discovery by using genomic and chemical data, and more.